ATE444062T1 - Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend - Google Patents

Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend

Info

Publication number
ATE444062T1
ATE444062T1 AT03740355T AT03740355T ATE444062T1 AT E444062 T1 ATE444062 T1 AT E444062T1 AT 03740355 T AT03740355 T AT 03740355T AT 03740355 T AT03740355 T AT 03740355T AT E444062 T1 ATE444062 T1 AT E444062T1
Authority
AT
Austria
Prior art keywords
cationic liposomal
liposomal preparation
lipophilic active
production
active substance
Prior art date
Application number
AT03740355T
Other languages
English (en)
Inventor
Carsten Mundus
Christian Welz
Oliver Schramel
Heinrich Haas
Thomas Fichert
Brita Schulze
Toralf Peymann
Gerhard Winter
Friedrich Gruber
Michael Teifel
Uwe Michaelis
Original Assignee
Medigene Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43384485&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE444062(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP02018724A external-priority patent/EP1374864A1/de
Application filed by Medigene Ag filed Critical Medigene Ag
Application granted granted Critical
Publication of ATE444062T1 publication Critical patent/ATE444062T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AT03740355T 2002-06-26 2003-06-26 Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend ATE444062T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39124502P 2002-06-26 2002-06-26
US39124602P 2002-06-26 2002-06-26
EP02018724A EP1374864A1 (de) 2002-06-26 2002-08-21 Amphiphile, Taxane enthaltende Zusammensetzungen
EP03004744 2003-03-04
PCT/EP2003/006759 WO2004002468A1 (en) 2002-06-26 2003-06-26 Method of producing a cationic liposomal preparation comprising a lipophilic compound

Publications (1)

Publication Number Publication Date
ATE444062T1 true ATE444062T1 (de) 2009-10-15

Family

ID=43384485

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03740355T ATE444062T1 (de) 2002-06-26 2003-06-26 Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend

Country Status (12)

Country Link
US (4) US7794747B2 (de)
EP (4) EP1530465B2 (de)
JP (1) JP4975964B2 (de)
AT (1) ATE444062T1 (de)
AU (1) AU2003280505B2 (de)
CA (1) CA2491216C (de)
CY (1) CY1118670T1 (de)
DE (1) DE60329497D1 (de)
DK (2) DK1530465T4 (de)
ES (1) ES2331791T5 (de)
PT (1) PT1530465E (de)
WO (1) WO2004002468A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039713A1 (en) 2001-10-19 2003-05-15 Innovative Construction And Building Materials, Llc Anti-pathogenic air filtration media and air handling devices having protective capabilities against infectious airborne microorganisms
ATE444062T1 (de) 2002-06-26 2009-10-15 Medigene Ag Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend
US6902797B2 (en) * 2002-11-12 2005-06-07 Innovative Construction And Building Materials Gypsum-based composite materials reinforced by cellulose ethers
AU2004283464B8 (en) * 2003-10-15 2011-04-14 Syncore Biotechnology Co., Ltd Method of administering cationic liposomes comprising an active drug
EP1676569A1 (de) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Gefriertrocknung von Virosomen
JP5700909B2 (ja) 2005-05-04 2015-04-15 メディゲーネ アクチエンゲゼルシャフトＭｅｄｉＧｅｎｅ ＡＧ パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法
CN100409846C (zh) * 2005-11-22 2008-08-13 菏泽睿鹰制药集团有限公司 一种埃坡霉素b脂质体制剂及应用
RU2448697C2 (ru) 2006-03-22 2012-04-27 Медигене Аг Лечение рака молочной железы, негативного по трем рецепторам
US20110002851A1 (en) * 2006-11-03 2011-01-06 Medigene Ag Cationic Colloidal Carriers for Delivery of Active Agents to the Blood-Brain Barrier in the Course of Neuroinflammatory Diseases
US20090319020A1 (en) * 2007-01-23 2009-12-24 Dtherapeutics, Llc Devices, systems, and methods for promoting endothelialization
CA2681302C (en) * 2007-03-19 2013-07-23 Dhiraj Khattar Proliposomal and liposomal compositions of poorly water-soluble compounds
EP2257277A1 (de) * 2008-04-04 2010-12-08 MediGene AG Solubilisierungsverfahren
DK2355851T3 (en) 2008-11-10 2018-06-25 Arbutus Biopharma Corp Newly known lipids and compositions for release of therapeutic agents
CN102361631A (zh) * 2009-03-25 2012-02-22 诺瓦提斯公司 含有药物和sirna的药物组合物
CA2781529C (en) 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes comprising docetaxel
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
EP2394640A1 (de) 2010-05-21 2011-12-14 MediGene AG Verbesserte liposomale Formulierungen von lipophilen Verbindungen
DE102011114951A1 (de) * 2011-10-06 2013-04-11 Forschungszentrum Jülich GmbH Molekülmischung, umfassend eine amphipathische Molekülsorte A, welche im hydrophilen Bereich elne positive Gesamtladung aufweist und eine amphipathische Molekülsorte B sowie ein Polyphenol C, Verfahren zur Herstellung der Molekülmischung und deren Verwendung
CN103110931B (zh) * 2013-03-19 2015-08-19 广州迈达康医药科技有限公司 制备罗咪酯肽脂质体的方法
WO2016045732A1 (en) * 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
CN107530291A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 双重负载的脂质体药物制剂
EP3283045B1 (de) 2015-04-13 2021-02-17 Fountain Technologies International, LLC Einstufiges verfahren zur herstellung von ultrakleinen lipidstrukturen
CN108289846B (zh) * 2015-12-08 2020-12-04 正大天晴药业集团股份有限公司 脂质体的制备方法
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
CN105853403B (zh) * 2016-05-09 2019-03-29 上海天氏利医药科技有限公司 一种紫杉醇棕榈酸酯脂质体及其制备方法
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
US20210236664A1 (en) * 2018-04-25 2021-08-05 The Johns Hopkins University Alpha particle formulations for treatment of solid tumors
CN110981837A (zh) * 2019-12-03 2020-04-10 沈阳药科大学 紫杉醇弱酸性衍生物主动载药脂质体及其制备与应用
CN110974972B (zh) * 2019-12-03 2023-01-20 沈阳药科大学 难溶性药物的弱酸性衍生物及其脂质体制剂
WO2021255262A1 (en) 2020-06-19 2021-12-23 Sylentis Sau siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
EP4015634A1 (de) 2020-12-15 2022-06-22 Sylentis, S.A.U. Sirna und zusammensetzungen zur prophylaktischen und therapeutischen behandlung von viruskrankheiten
AU2022371688A1 (en) * 2021-10-22 2024-06-06 Ohio State Innovation Foundation Compositions and methods of the delivery of active agents including nucleic acids
WO2023123986A1 (zh) 2021-12-31 2023-07-06 成都华昊中天药业有限公司 优替德隆脂质体组合物及其制备方法和用途
US20260069541A1 (en) * 2022-08-25 2026-03-12 Ohio State Innovation Foundation Compositions and methods for the delivery of active agents including nucleic acids
JP2026505783A (ja) 2023-01-31 2026-02-18 石薬集団中奇制薬技術（石家庄）有限公司 腫瘍を治療するためのパクリタキセルカチオンリポソームの使用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
DE69329073T2 (de) 1992-03-23 2001-01-18 Georgetown University, Washington In liposomen verkapseltes taxol und verwendungsverfahren
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
CA2149150C (en) * 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
JPH06211645A (ja) * 1993-01-14 1994-08-02 Mitsubishi Kasei Corp リポソーム凍結乾燥製剤
AU6833994A (en) 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
PT1118325E (pt) 1993-07-29 2006-05-31 Us Health Utilizacao de paclitaxel e seus derivados na preparacao de um medicamento para o tratamento de restenose
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
DE4430593C2 (de) 1994-08-20 1999-01-14 Max Delbrueck Centrum Verfahren zur Herstellung von Liposomal verkapseltem Taxol
DE4432378A1 (de) 1994-09-12 1996-03-14 Bayer Ag Injizierbare liposomale Arzneizubereitungen
AU3740997A (en) 1996-08-26 1998-03-19 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
WO1998017256A1 (en) * 1996-10-22 1998-04-30 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
WO1998022451A1 (en) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
US6034072A (en) * 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
WO1998051278A2 (en) 1997-05-14 1998-11-19 Inex Pharmaceuticals Corporation High efficiency encapsulation of charged therapeutic agents in lipid vesicles
DE69820465T2 (de) * 1997-06-23 2004-09-16 Alza Corp., Mountain View Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
AU741433B2 (en) 1997-10-08 2001-11-29 Bio Research Corporation Of Yokohama Taxoid derivatives and process for producing the same
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
DK1059092T3 (da) * 1999-06-08 2006-03-27 Gentium Spa Anvendelse af komplekser af kationiske liposomer og polydeoxyribonukleotider som medikamenter
CN1228041C (zh) 1999-07-15 2005-11-23 英耐克斯药品股份有限公司 脂质包埋的治疗剂的制备方法
GB9918429D0 (en) 1999-08-04 1999-10-06 Novartis Ag Organic compounds
HUP0202669A3 (en) * 1999-09-09 2004-06-28 Univ California Cationic liposome delivery of taxanes to angiogenic bloos vessels
US6348215B1 (en) * 1999-10-06 2002-02-19 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
WO2001056548A2 (en) 2000-02-04 2001-08-09 Lipoxen Technologies Limited Liposomes composition produced by a dehydration-rehydration process
PL366025A1 (en) * 2000-05-03 2005-01-24 Munich Biotech Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
JP2003535832A (ja) 2000-06-09 2003-12-02 ブリカス，テニ ポリヌクレオチドおよび薬物の標的化リポソームへのカプセル化
US6680068B2 (en) * 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ATE444062T1 (de) * 2002-06-26 2009-10-15 Medigene Ag Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend
ITPD20020271A1 (it) * 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.

Also Published As

Publication number Publication date
DK2286795T3 (en) 2017-02-06
ES2331791T5 (es) 2016-01-21
EP1530465B2 (de) 2015-12-16
US20050202076A1 (en) 2005-09-15
DK1530465T3 (da) 2010-02-01
CA2491216A1 (en) 2004-01-08
US20120087975A1 (en) 2012-04-12
EP2277507A1 (de) 2011-01-26
PT1530465E (pt) 2010-01-05
CA2491216C (en) 2012-01-03
EP2286795A1 (de) 2011-02-23
US20110038926A1 (en) 2011-02-17
US7794747B2 (en) 2010-09-14
EP1530465B1 (de) 2009-09-30
EP2286795B1 (de) 2016-10-26
EP2108362A2 (de) 2009-10-14
EP1530465A1 (de) 2005-05-18
EP2108362A3 (de) 2010-12-15
US8663606B2 (en) 2014-03-04
CY1118670T1 (el) 2017-07-12
EP2108362B1 (de) 2013-05-29
DE60329497D1 (de) 2009-11-12
ES2331791T3 (es) 2010-01-15
US8075913B2 (en) 2011-12-13
JP4975964B2 (ja) 2012-07-11
DK1530465T4 (en) 2016-03-21
AU2003280505B2 (en) 2009-01-15
AU2003280505A1 (en) 2004-01-19
US9238021B2 (en) 2016-01-19
US20140205657A1 (en) 2014-07-24
JP2005535730A (ja) 2005-11-24
WO2004002468A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
ATE444062T1 (de) Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend
WO2005065185A3 (en) Temperature-stable formulations, and methods of development thereof
WO2002014323A3 (en) Polymorphs of an epothilone analog
BRPI0409133B8 (pt) preparações farmacêuticas estavéis compreendendo metilnaltrexona
BR0107425A (pt) Processo para a preparação compostos de derivados de ácido 3-hidróxi picolìnico e uso dos compostos
BRPI0510599A (pt) compostos, processo para a preparação dos mesmos, composição farmacêutica, uso de um composto, e método para o tratamento e a profilaxia de doenças
WO2003043631A3 (en) Method for identification of tumor targeting enzymes
NO20034149L (no) Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel
CA2506016A1 (en) 3-amino-piperidine derivatives and processes for their preparation
DE602004016856D1 (de) Hfc lösungsformulierungen enthaltend ein anticholinergikum
WO2003014079A8 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
EA200401583A1 (ru) Таблетка лазофоксифена и ее покрытие
WO2006125620A3 (en) Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
ATE415817T1 (de) Agrochemische formulierungen
BR0313162A (pt) Composto, processo para preparar o mesmo, e, composição farmacêutica
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
BR0311984A (pt) Difenilazetidinonas substituìdas cationicamente, processo para a sua preparação, medicamentos contendo estes compostos e sua aplicação
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
ATE332894T1 (de) Ein pyridin-n-oxid-derivat und ein prozess zu seiner umsetzung in pharmazeutische wirkstoffe
WO2002030467A3 (en) Pharmaceutical composition containing honey for the treatment of wounds
WO2004062562A3 (en) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
WO2001049654A3 (de) Substituierte aminomethyl-phenyl-cyclohexanderivate
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
WO2005102248A3 (en) Silicone vesicles containing actives

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1530465

Country of ref document: EP